TrialThe lancet. HIV2016

Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.

Alberto M La Rosa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.